Novel anti-CD38 humanized mAb SG003 possessed enhanced cytotoxicity in lymphoma than Daratumumab via antibody-dependent cell-mediated cytotoxicity

Tao Yu†, Chunxia Qiao†, Ming Lv§ and Luqn Tang*‡

Abstract

Background: In vivo use of monoclonal antibodies has become routine clinical practice in the treatment of human cancer. CD38 is an attractive target, because it has double roles, as a receptor and an ectoenzyme. Daratumumab, an anti-CD38 antibody, is currently in the clinical trials for multiple myeloma.

Results: Here we obtained a humanized anti-CD38 antibody, SG003, using SDR-grafting method. SG003 possessed stronger antigen binding activity than Daratumumab, and its epitope was far from that of Daratumumab, an anti-CD38 antibody currently in the clinical trials for multiple myeloma; besides, SG003 showed enhanced antibody-dependent cell-mediated cytotoxicity function and in vivo inhibitory efficacy of tumor growth in xenograft mice model.

Conclusion: SG003 seemed to be a good option to improve the curative effect of CD38-related cancers.

Keywords: CD38, Daratumumab, Monoclonal antibody, SDR-grafted humanization
e.g. leukemia cells, or patient MM tumor cells. Nijhof et al. [8] reported that in bone marrow samples, Daratumumab induced both CDC and ADCC in vitro effectively, and there is a significant association between Daratumumab-induced CDC/ADCC and the expression level of CD38 in MM patients. Recently, Schutte et al. have generated a CD38-specific biparatopic heavy chain antibodies, which elicited CDC toward CD38-expressing myeloma cells more effectively than daratumumab [9].

The satisfactory function of Daratumumab in preclinical research led to its clinical trials. In the first phase 1/2 clinical trial, Daratumumab was administered as a single agent in relapsed/refractory myeloma patients. In the group of 16 mg/kg, the ORR (overall response rate) was 36%, and the DOR (median duration of response) was not reached; besides, the rate of PFS (progression-free survival) over 12-month reached up to 65% [10, 11]; then, in the phase II trial (SIRIUS), the median PFS of MM patients was 3.7 months, and 12-month OS (overall survival) rate was 64.8% [12]; In SIRIUS and GEN501 studies [13], the ORR was 31%, and the OS was about 19.9 months, demonstrating that Daratumumab monotherapy was beneficial in patients with pre-treated and/or relapsed/refractory myeloma [14, 15]; meanwhile, Daratumumab is also under investigation in combination with other MM regimens [16]; Besides, two additional anti-CD38 antibodies have also entered clinical trials for MM and other CD38+ hematologic malignancies, MOR202 [17, 18] and isatuximab (SAR650984) [19], that are being tested alone and in combination with standard therapy.

In chronic lymphocytic leukemia (CLL), CD38 is also one of the surface molecular markers for clinical use [20]. It is now generally accepted that CD38+ leukemia patients have a shorter progression-free interval, require earlier and more frequent treatments, and ultimately lower survival rate. Daratumumab was tested to have anti-tumor activity in leukemia [21, 22]. Recently, our team screened a mouse-anti-CD38 mAb, 3G3, by hybridoma technology, which showed good anti-leukemia activity in vitro. Here we humanized 3G3 to have a SDR-grafted antibody, SG003, whose affinity to bind CD38 was higher than Daratumumab, and the epitope of SG003 was different from that of Daratumumab; moreover, SG003 showed stronger ADCC function and in vivo inhibitory efficacy of tumor growth in xenograft mice model, suggesting its potential to achieve improved curative effect in patients with leukemia.

Results

SG003 possessed stronger antigen binding activity than Daratumumab

3G3 was humanized using CDR- or SDR-grafting method, and SG003, which was obtained from SDR-grafting, was identified similar to 3G3 in CD38 binding. As shown in Fig. 2a, ELISA assay displayed satisfactory bio-function of both CDR-grafted 3G3 (anti-CD38-CDR) and SDR-grafted 3G3 (anti-CD38-SDR, also named SG003) to bind the soluble CD38 on a dose-dependent manner, which was similar to 3G3; furthermore, according to the BiAcore analysis data, SG003 possessed similar affinity to 3G3 (Fig. 2b), with the Ka and Kd value of 2.86*10^6 1/Ms and 9.18*10^-4 1/s, respectively (Table 1).

Meanwhile, we compared SG003 with the first-in-class anti-CD38 therapeutic antibody Daratumumab. Dosage ELISA showed the EC50 value of SG003 as 0.0498 μg/mL to bind the coated sCD38, which is ~6 times stronger than Daratumumab (EC50 = 0.3005 μg/mL); moreover, the maximum OD value of SG003 was obviously higher than Daratumumab (Fig. 3a, 2.4 of SG003 V.S. 1.5 of Daratumumab); Similarly, flow cytometry assays also showed that SG003 had stronger cell surface CD38-binding activity than Daratumumab in either Raji (Fig. 3b) or Daudi (Fig. 3c) cells. More importantly, the mean value of SG003 group was much higher, suggesting that SG003 might bound to the extracellular domain of CD38 in vivo, thus possibly induce stronger cytotoxicity. More importantly, SG003 had no/weak cross-reactivity to bind CD38- tumor cells (e.g. 293 T) by flow cytometry detection (Fig. 4a), or a series of extracellular domain of many receptors/glyco-proteins (e.g. CD47, CD19, AXL, TROP2, GAS6, etc.) by ELISA detection (Fig. 4b).

The epitope of SG003 was different from that of Daratumumab

Using antibody homological modeling, molecular docking, and dynamic simulation methods, we constructed the theoretical structure of CD38 and SG003 complex (Fig. 5a), according to which the potential epitope of SG003 located in V194 R195 R198 E233 E234 K of CD38. Then, a series of CD38 mutants were designed using alanine replacement (Fig. 5b) and displayed on 293 T cell surface method. As shown in Fig. 5c, SG003 couldn’t bind to these mutants, confirming the importance of residues 76–79, 107–117, 194–198 and 233–234 to recognize SG003. Meanwhile, the epitope of Daratumumab was 233–246 and 267–280 of CD38 [7], which was far
from that of SG003; Moreover, in ADCC assays, the EC50 value of SG003 was 0.0146 μg/mL in Raji (Fig. 6a), and 0.00056 μg/mL in Daudi cells (Fig. 6b), both of which were lower than that of Daratumumab (0.0262 and 0.0033 μg/mL, respectively). We inferred SG003’s epitope might contribute to its stronger ADCC function, even though the mechanism was unknown to need further study.

SG003 inhibits the growth of xenograft tumor in SCID mice
Prior to cell injection, SCID mice were healthy with the body weight of 17~18 g/mouse. Mice were injected subcutaneously with CD38+ Raji cells. After ~7 days, SG003 were divided into 3 groups (n = 6) and inoculated i.v. with Daratumumab, SG003 or isotype control. Figure 7a showed the light emission of mice from the back side. The two groups of antibody-treated mice carried much smaller lump than the control group; more interestingly, SG003 seemed to inhibit the growth of Raji xenografts similar to Daratumumab. We were pleased to see that 2/6 mice had relapsed tumor in SG003 group (mouse number 32170 and 32,223); besides, the survival rate also testified SG003’s stronger anti-tumor activity in vivo (G3 group) --- 3/6 mice survived at the endpoint, which was higher than the control group (G1, all mice were dead) and even the Daratumumab-treated mice (G2, 5/6 mice dead) (Fig. 7b), suggesting SG003 might have better potential in in vivo cancer therapy.

Discussion
CD38 is a type 2 transmembrane protein, and its molecular weight (MW) is approximately 45 kDa. CD38 is a single chain protein, however, its functional structure is a dimer or a multimer [23–25]. CD38 can help synthesize the ADP-ribose from NAD to increase the cytoplasmic Ca2+ concentration. CD38 does not bind to the BCR complex, and it tends to aggregate in discrete membrane lipid micro domains to BCR in CLL cells [21]. CD38 also exert the same membrane distribution for TCR on T lymphocytes and CD16 on NK cells [26, 27]. Besides, CD38 can induce the phosphorylation of the intracellular substrate cascades to trigger the cytokine secretion and/or T lymphocyte proliferation [28].

CD38 is used as a disease marker for leukemia and myeloma and it is considered a negative prognostic marker for CLL. In most of MM patients, CD38 was found positive and several anti-CD38 mAbs have been screened out to enter the clinical trials; in CLL cells, CD38 was also considered to form a complex network delivering survival signals, which made CD38 an attractive target for CLL therapy.

Daratumumab that specifically binds to CD38 was the first therapeutic anti-CD38 drug approved by FDA for patients with MM [10, 12]. Daratumumab was shown to facilitate cell killing in various hematological tumors mainly via CDC, ADCC [7], and/or apoptosis upon
secondary cross-linking [29]. It also induced the cytotoxicity of MM tumor cells in patient via CDC and ADCC to suggest its high anti-tumor activity in vivo.

In mouse model with the CD38+ CLL MEC2 cells and patient-derived xenografts (CLL-PDX), Daratumumab improved the overall survival rate of MEC2 mice significantly [22]. Besides, Homing of CLL cells to lymphoid organs is mainly coordinated by the CXCL12/CXCR4 axis. The effect of Daratumumab on CLL cells was demonstrated by inhibiting CXCL12-induced migration in vitro and interfering patient-derived CLL cells’ homing to spleen in NSG mice in vivo. Vaisitti et al. demonstrated CD38 together with CXCR4 controls homing of CLL cells because of CD38-CXCR4 interaction both in CLL primary cells and a xenograft mouse model [30]. Daratumumab also reduced CD49d mediated CLL cell adhesion by reducing MMP9 levels [22]. These unique and substantial effects of Daratumumab supported the possibility of anti-CD38 antibodies in clinical use of CLL patients.

Ghose et al. [31] have demonstrated that Daratumumab impairs multiple myeloma cell adhesion, which leads to an increased sensitivity of multiple myeloma to proteasome inhibition. Daratumumab was also shown to induce CDC in cancer cells from MM patients, similar to alemtuzumab (CD52 mAb), which has been found to kill B cell tumor cells mainly via CDC [32]. Interestingly, Daratumumab was demonstrated efficient to kill patient-derived CLL cells by ADCC in vitro, while exhibited negligible CDC in these cells [22], however, the reason why Daratumumab showed limited CDC activity in both primary CLL cells and CLL cell lines kept unknown. Here we screened a novel anti-CD38 antibody 3G3, which possessed enhanced cytotoxicity in B lymphocytes than Daratumumab via ADCC (Fig. 1). Then we humanized it to obtain SG003, a SDR-grafted mAb, whose affinity was similar to 3G3 (Fig. 2 & Table 1). We also noticed the predominant ADCC function triggered by SG003, which was much stronger than Daratumumab (Fig. 6), while its CDC function was too weak to be detected (data not shown).

Evidence suggest that the positioning of mAbs after binding to its antigen may be ideal for complement

**Table 1** Affinity constant of anti-CD38 antibodies. The SDR-grafted 3G3 (Anti-CD38-SDR) had similar/a little bit higher Ka and Kd value to 3G3, therefore its affinity constant is similar to 3G3

| Affinity constant to CD38-ECD-His | ka (10^4 1/Ms) | kd (10^4 1/s) | KD (10^16 M) | Chi² |
|----------------------------------|----------------|--------------|-------------|------|
| Anti-CD38                        | 2.36 ± 0.13    | 5.30 ± 0.08  | 2.25 ± 0.09 | 0.49 ± 0.14 |
| Anti-CD38-CDR                    | 2.66 ± 0.01    | 6.36 ± 0.05  | 2.39 ± 0.03 | 0.26 ± 0.06 |
| Anti-CD38-SDR                    | 2.86 ± 0.00    | 9.18 ± 0.01  | 3.21 ± 0.01 | 0.22 ± 0.02 |

* The values represent mean ± standard error.
activation [33], and this may also exist in Daratumumab. In fact, induction of CDC was a very specific character of Daratumumab contrasting to other CD38 mAbs. Epitope mapping and site directed mutagenesis assays revealed its unique epitope, which might cluster and position its Fc region in a fine situation that permitted more optimal activation of complements. Here the affinity of SG003 was stronger than Daratumumab (Fig. 3), and its epitope was distinct (Fig. 5). We assumed that the distinct epitope of SG003 might contribute to its

![Fig. 3](image1.png)  
**Fig. 3** SG003 (the SDR-grafted 3G3, Anti-CD38-SDR) possessed stronger antigen binding activity than Daratumumab. ELISA analysis (a) showed the EC50 value of SG003 to bind coated CD38 (0.0498 μg/mL), which is ~ 6 times stronger than that of Daratumumab (EC50 = 0.3005 μg/mL), while the maximum OD value of SG003 was also higher obviously than Daratumumab; Similarly, in either Raji or Daudi cells, flow cytometry assays also showed stronger activity of SG003 than Daratumumab to bind membrane CD38, for the EC50 value was 0.0344 or 0.0380 μg/mL in SG003-treated Raji (b) or Daudi (c) cells, and more importantly, the mean value was also much higher in SG003-bound cells, suggesting that SG003 might induce stronger tumor killing effect

![Fig. 4](image2.png)  
**Fig. 4** SG003 had no/weak cross-reactivity to a series of glycoproteins. a flow cytometry analysis of SG003 to bind 293 T cells (CD38 negative); b SG003 didn’t bind to the extracellular domain of many receptors, e.g. CD47, CD19, BSA, etc. by ELISA detection
stronger ADCC but weaker CDC function in B lymphocytes as well as the stronger activity to inhibit the growth of xenografts in vivo and improve the survival rate of SCID mice (Fig. 7), although further studies should be done to confirm it.

**Conclusion**
Contrasting to the first therapeutic anti-CD38 antibody Daratumumab, 3G3 possessed higher affinity, unique epitope, stronger ADCC function, as well as better in vivo curative effect. 3G3 seemed to be a good candidate with the potential to offer better therapeutic efficacy, especially in CD38+ leukemia patients.

**Methods**
**Reagents**
CD38 protein was purchased from Sino biological (Cat. No: 10818-H08H); Darzalex (Daratumumab) was purchased...
from Janssen Biotech; Human IgG Isotype control (Cat. No.: 02–7102) and HRP conjugated Goat anti-Human IgG (H + L) Secondary Antibody (Cat. No.: # A18805, dilution for ELISA: 1:2000) FROM Invitrogen; PE conjugated Goat anti-human polyclonal antibody (PE_GAH) were from eBiosciences (Cat. No.: 12–4998-82, Dilution for flow cytometry: 1:50); Dulbecco's modified Eagle medium (DMEM) (Cat. No. 11965–092), RPMI 1640 (Cat. No. 11875–093), and fetal bovine serum (FBS) (Cat. No. 10438–034) were purchased from Thermo Fisher; DELFIA EuTDA Cytotoxicity Reagents was purchased from Perkin Elmer (Cat. No. AD0016); All other chemicals were obtained from commercial source of analytical grade.

Cell lines
Human embryonic kidney epithelial cells 293 T (ATCC® CRL-3216™), B Lymphocyte Raji (ATCC®CCL-86™) and B Lymphoblast Daudi (ATCC®CCL-213™) were obtained from American Type Culture Collection (ATCC); Raji-luc lymphoma cells were generated as described previously to let Raji cells express luciferase [34, 35]; Human peripheral blood mononuclear cells (PBMC) were extracted from the whole blood using Ficoll-Paque Plus (GE Healthcare, Cat. No. 17–1440-02); 293 T were cultured in DMEM, while Raji and Daudi were cultured in RPMI-1640 (Gibco, Cat. No. 11875–093). Media was supplemented with 10% heat-inactivated FBS (Gibco, Cat. No. 26010–074) and 100 units/mL penicillin & streptomycin (Gibco, Cat. No. 15140–122). Cells were tested without mycoplasma contamination (LookOut Mycoplasma PCR detection kit, Cat. No. MP0035, Sigma-Aldrich, MO, USA) and cultured at 37 °C in 5% CO2.

Antibody generation
Anti-CD38 Antibody 3G3 were generated by immunization of mice with recombinant CD38 protein. After isolation of

---

**Fig. 7** SG003 inhibits outgrowth of CD38-expressing Raji xenografts in SCID mice model. **a** Light emission of mice from the back side. SCID mice were inoculated with luciferase-expressing Raji cells, and 100 μg/mouse SG003 was injected to inhibit the tumor growth. Mice infused with Daratumumab or human IgG (100 μg/mouse) were set as positive or negative controls. **b** Survival Rate of Raji xenograft mice (n = 6). The experiments were done twice SG003 had satisfactory anti-tumor activity in vivo. 3 mice in SG003 group were alive at the endpoint, which was obviously higher than control group (G1, all dead), and even the Daratumumab-treated group (G2, 1 mouse alive).
mouse splenocytes and fusion, the hybridomas were tested for binding to CD38 by indirect ELISA, from which 3G3 was selected based on its high affinity and then its unique cytotoxicity ability of Raji cells. In all experiments, human IgG polyclonal antibody (pAb) was used as negative control.

According to the theoretical analysis, simulation and design, the VH/VL genes of CDR- or SDR-grafted 3G3 antibodies were obtained, then the humanized antibodies were prepared using our Flp-FRT mammalian system [36].

**ELISA**

ELISA plates were coated with antigen (e.g. 2 μg/mL CD38 protein) at 4 °C overnight and then blocked with 1% BSA in PBS containing 0.05% Tween-20 for an hour at 37 °C. Diluted antibodies were added as first antibody and incubated for 2 hours at 37 °C. After washing, horseradish peroxidase conjugated goat anti-human IgG was added for an hour’s incubation at room temperature. Binding signals were visualized using TMB substrate and the light absorbance was measured with an ELISA reader at 450 nm.

**Cytotoxicity assay (ADCC)**

ADCC activities of the antibodies were measured by DELFIA EuTDA Cytotoxicity Reagents (Perkin Elmer) according to the manufacturer’s instructions. Briefly, the tumor cells (target cells) were incubated with fluorescence-enhancing ligand, then incubated with the anti-CD38 antibodies for 1 h at 37 °C, followed by the addition of the effector cells, human peripheral blood mononuclear cells (PBMC) (effector:target = 50:1). After an additional incubation for 4 h at 37 °C, the fluorescence of the supernatant was measured in a time-resolved fluorometer. Maximum release was determined by cell lysis in 0.2% Triton X-100. Percentage of lysis in each mAb-treated sample was calculated according to the following formula:

\[
\text{\%Inhibition} = \frac{\text{[experimental release} - \text{minimum release}]}{\text{[maximum release} - \text{minimum release}]}
\times 100.
\]

**Computer-aided humanization and epitope prediction**

The 3-D structure of CD38 or 3G3 were constructed by computer-guided homology modeling method using InsightII version 2005 (Molecular Simulations, San Diego, CA). According to the potential epitope of CD38, the 3-D complex structure of CD38 and 3G3 was modeled with molecular docking method and optimized using the modules Discover and CHARMM in InsightII. The non-bonded cutoff was 10 Å, non-bonded parameters and atomic charges were taken as defaults. A distance dependent dielectric constant was used as in vacuo calculations. The model was minimized using steepest descent (2000 steps) and conjugate gradient (5000 steps) methods, respectively.

Based on the complex structure, the six CDRs of 3G3 were kept while the FR regions were replaced to human sites, which offered CDR-grafted 3G3; meanwhile, the core sites of 3G3-CDRs were kept, and the FR regions as well as both ends of six CDRs were replaced to human residues, giving birth to SDR-grafted 3G3.

According to the theoretical structure of extracellular regions of human CD38 (CD38_ECD) and antibody (e.g. 3G3) complex, the potential epitopes were predicted, by which a series of CD38 mutants were designed.

**BIACore**

The antigen, commercial CD38 recombinant protein, was set as fluid phase. The parent antibody 3G3 was set as positive control, and the solvent (sample buffer) was set as negative control. The background was deducted according to the V-baseline in order to obtain the kinetic curves and calculate the dissociation constant (K_d value).

**Flow cytometry**

Raji or Daudi cells were washed and then incubated with serial dilutions of mAbs or isotype IgG control. After washing and incubation with PE_GAH, samples were determined using BD FACS Calibur and the fluorescence density was analyzed with BD CellQuest Pro software. Experiments were performed on ice.

In epitope identification assay, using alanine replacement, a series of CD38 mutants were expressed on 293 T cell surface. Then cells were incubated with SG003 and then PE_GAH for detection.

**In vivo assays in mice**

Eighteen female, 8- to 10-wk-old C.B-17 SCID mice (C.B-17/LcrCrl-scid-BR) were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. and housed in filter-top cages (3 mice per cage) in SPF-level Facility fed with Sterilized food and water. During the animal assays, we followed the ARRIVE guidelines for the use of mice (https://www.nc3rs.org.uk/arrive-guidelines). We noticed animal ethics during the research with 3R principles (Replacement, Reduction and Refinement), and use or treatment of mice were in strict agreement with the guidelines for the care and use of research animals and approved by the Animal Ethics Committee of Beijing Institute of Pharmacology and Toxicology (Ethic permission number: PTAE2017010). Mice were checked at least three times a week for signs of discomfort and for general appearance. After the study, the mice were
sacrificed using anesthesia by i.p. injection of 80 mg/kg ketamine, 20 mg/kg xylazine and 0.6 mg/kg atropine, and then the cervical dislocation method, and we used deep-freezing to confirm the death.

For the xenograft model, 2.5 × 10^6 Raji-luc cells per mouse were injected s.c.. In a week, mice were randomly divided into three groups, administered i.v. with 5 mg/kg of anti-CD38 mAb or human IgG isotype control, and observed twice a week for 4 weeks after administration of antibody (n = 6). On day 28, mice were injected i.p. with synthetic D-luciferin (acid form) and luminescence was measured. For imaging, mice were anesthetized by i.p. injection of 80 mg/kg ketamine, 20 mg/kg xylazine, and 0.6 mg/kg atropine mixture before D-luciferin was given in 2.5 mg/200 µl 10 mM Tris base/mouse. Imaging of each mouse was done using a VersArray 1300B device detector (Roper Scientific, Vianen, Netherlands) and photons emitted from the luciferase system were counted after an exposure period of 5 min. The experiments were done twice. MetaVue software (purchased from Molecular Devices) was used for data collection and analysis.

Statistical analysis
All experiments were done at least two times. Data are expressed as mean ± SD. Pair wise differences between several groups were compared. Statistical analysis was performed by Student test or by repeated measures one-way ANOVA. Treatments were taken as statistically significant when P-values of less than 0.05.

Abbreviations
ADCC: Antibody-dependent cell cytotoxicity; ATCC: American Type Culture Collection; BCR: B cell receptor; BM: Bone marrow; CDC: Complement-dependent cytotoxicity; DMEM: Dulbecco’s modified Eagle medium; DOR: Median duration of response; FBS: Fetal bovine serum; mAb: Monoclonal antibody; MM: Multiple myeloma; MW: Molecular weight; ORR: Overall response rate; OS: Overall survival; PFS: Progression-free survival

Acknowledgements
We thank Prof. Jiannan Feng for giving valuable suggestion in antibody modeling and humanization.

Funding
This work was supported by grants from National Sciences Fund (No. 31370938, No. 81272528). The Fund (No. 31370938) helped design the study and collected the data for analysis. The Fund (No. 81272528) offered experiment material and was helpful in writing the manuscript.

Availability of data and materials
The datasets used and/or analyzed during the current study is available from the authors upon a reasonable request.

Authors’ contributions
YT did antigen binding and ADCC assays; QC did the modeling and humanization of antibody, in vivo assays in mice and wrote the manuscript; LM did gene cloning and antibody purification; TL designed experiments and supervised the study, and revise the manuscript. All authors have read and approved the manuscript.

Ethics approval and consent to participate
The use or treatment of mice were in strict agreement with the guidelines for the care and use of research animals and approved by the Animal Ethics Committee of Beijing Institute of Pharmacology and Toxicology.

Consent to participate: Not Applicable.

Consent for publication
Not Applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China. 2State key laboratory of Pharmacology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, 27 Taiping Road, Beijing 100850, China. 3Sumgen Biotech co., Ltd., Hangzhou 310000, China. 4Department of Radiation Oncology, the Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, China.

Received: 15 November 2018 Accepted: 7 May 2019
Published online: 22 May 2019

References
1. Mahavi A, Deaglio S, Funaro A, Ferroero E, Horestein AL, Ortolan E, Vaissiti T, Aysdin S. Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol Rev. 2008;88(3):841–86.
2. Chen J, Feliotte HE, Pare CG, Zhang X, Pemberton JG, Garady C, Lai D, Yang X, Tion VA. MicroRNA-193b represses cell proliferation and regulates cyclin D1 in melanoma. Am J Pathol. 2010;176(5):2520–9.
3. Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol. 2004;121(4):482–8.
4. Magarotto V, Salvinii M, Bonello F, Brighen S, Palumbo A. Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: a new era begins. Leuk Lymphoma. 2016;57(12):357–56.
5. Sondergeld P, van de Donk NW, Richardson PG, Plesner T. Monoclonal antibodies in myeloma. Clin Adv Hematol Oncol. 2015;13(9):599–609.
6. Jiang H, Acharya C, An G, Zhong M, Feng X, Wang L, Dasilva N, Song Z, Yang G, Adrian F, Qiu L, Richardson P, Munshi NC, Tai YT, Anderson KC. SAR650984 directly induces multiple myeloma cell death via lysisosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide. Leukemia. 2016;60(2):399–408.
7. de Weers M, Tai YT, van der Veen MS, Bakker JM, Vink J, Jacobs DC, Oomen LA, Peipp M, Valerius T, Sbooth JW, Mutis T, Bleeker WK, Anderson KC, Lokhorst HM, van de Winkel JG, Parren PW. Daratumumb, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840–8.
8. Nijhof IS, Groen RW, Lokhorst HM, van Kessel B, Bloem AC, van Velzen J, de Jong-Korlaar R, Yuan H, Noort WA, Klein SK, Martens AC, Deoii P, Sasser K, Mutis T, van de Donk NW. Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab. Leukemia. 2015;29(10):2039–49.
9. Schutze K, Kett Y, Harmbach J, Schuster N, Fumey W, Schriewer L, Rockendorf J, Menzel S, Albrecht R, Haag F, Sterner C, Bannas P, Koch-Nolte F. CD38-specific Biparatopic heavy chain antibodies display potent complement-dependent cytotoxicity against multiple myeloma cells. Front Immunol. 2018;9:2553.
10. Lokhorst HM, Plesner T, Laubach JP, Nahi H, Ginsing P, Hansson M, Minnema MC, Lassen U, Krejci J, Palmajo A, van de Donk NW, Ahmadi T, Khan I, Uhlar CM, Wang J, Sasser AK, Loic N, Liney S, Basse L, Brun N, Richardson PG. Targeting CD38 with Daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373(13):1207–19.
11. Nijhof IS, Groen RW, Noort WA, van Kessel B, de Jong-Korlaar R, Bakker J, van Bueren JJ, Parren PW, Lokhorst HM, van de Donk NW, Martens AC, Mutis T. Preclinical evidence for the therapeutic potential of CD38-targeted Immuno-chemotherapy in multiple myeloma patients refractory to Lenalidomide and Bortezomib. Clin Cancer Res. 2015;21(12):2802–10.
12. Lonial S, Weiss BM, Usmani SZ, Singhal S, Char A, Bahls NI, Belch A, Krishnan A, Vescio RA, Mateos MV, Mazumder A, Orlowski RZ, Sutherland HI, Blade J, Scott EC, Orid A, Berdeja J, Gharibio M, Stevens DA, LeBlanc R, Sebag M, Callander N, Jakubowiak A, White D, de la Rubia J, Richardson PG, Lisy S, Feng H, Uhlar CM, Khan I, Ahmadi T, Voorhees PW. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SRILUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387(1007):1551–60.

13. Nijhof IS, Casneuf T, van Velzen J, van Kessel B, Abel AE, Syed K, Groen RW, van Duin M, Sonneveld P, Minnema MC, Zweegman S, Chiu C, Bloem AC, Mutis T, Lokhorst HM, Sasser AK, van de Donk NW. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood. 2016;128(7):595–70.

14. Richardson PG, Siegel DS, Vier R, Hofmeister CC, Baz R, Jagannath S, Chen C, Lonial S, Jakubowiak A, Bahls N, Song K, Belch A, Raje N, Shustik C, Lenzscht S, Lacy M, Mikhael J, Matouk J, Vesole D, Chen M, Zaki MH, Jacobs C, Yu Z, Anderson KC. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomised phase 2 study. Blood. 2014;123(12):1826–32.

15. Siegel DS, Martin T, Wang M, Vrj R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, Belch A, Krishnan A, Vescio RA, Mateos MV, Mazumder A, Orlowski RZ, Sutherland HI, Blade J, Scott EC, Orid A, Berdeja J, Gharibio M, Stevens DA, LeBlanc R, Sebag M, Callander N, Jakubowiak A, White D, de la Rubia J, Richardson PG, Lisy S, Feng H, Uhlar CM, Khan I, Ahmadi T, Voorhees PW. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SRILUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387(1007):1551–60.

16. McGirt LY, Jia P, Baerenwald DA, Duszynski RJ, Dahlman KB, Zic JA, Zwerner JP, Richardson PG, Malavasi F. CD38 antibodies in multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia. 2018;32(2):252–62.

17. van de Donk N, Richardson PG, Malavasi F. CD38 antibodies targeting CD38 and SLAMF7 in multiple myeloma. Blood. 2016;127(6):681–95.

18. Zent CS, Secreto CR, LaPlant BR, Bone ND, Call TG, Shanafelt TD, Jellinek DF, Tschumper RC, Kay NE. Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab. Leuk Res. 2008;32(12):1849–56.

19. Pavlučkowycz AW, Beurslins FJ, Beum PV, Lindorfer MA, van de Winkel JG, Parren PW, Taylor RP. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs cutaBo (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J Immunol. 2009;183(1):749–58.

20. Ruzzemuller H, van der Spek E, Bogers-Boer LH, Zwart MC, Verweij V, Emmelot M, Groen RW, Spaapen R, Bloem AC, Mutis T, Martens AC. A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect. Haematologica. 2008;93(7):1049–57.

21. Kuipers J, Vaandrager JW, Weghuis DO, Pearson PL, Scheres J, Lokhorst HM, Clevers H, Bast BJ. Fluorescence in situ hybridization analysis shows the frequent occurrence of 14q32.3 rearrangements with involvement of immunoglobulin switch regions in myeloma cell lines. Cancer Genet Cytogenet. 1999;109(2):99–107.

22. Luo L, Wang S, Lang X, Zhou T, Geng J, Li X, Qiao C, Feng J, Shen B, Lu M, Li Y. Selection and characterization of the novel anti-human PD-1 Fv78 antibody from a targeted epitope mammalian cell-displayed antibody library. Cell Mol Immunol. 2018;15(2):146–57.

23. Overdijk MB, Jansen JH, Nedermond M, Lammerts van Bueren JJ, Groen RW, Parren PW, Leusen JH, Boross P. The therapeutic CD38 monoclonal antibody Daratumumab induces programmed cell death via Fc gamma receptor-mediated cross-linking. J Immunol. 2016;197(3):807–13.

24. Van Rees TC, Gans S, Selig H, Donahue CM, Fontana R, Bunn PA, Kneuer O, Wiestner A, Parren PW, Taylor RP. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs cutaBo (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J Immunol. 2009;183(1):749–58.

25. Zhao YJ, Lam CM, Lee HC. The membrane-bound enzyme CD38 exists in two opposing orientations. Sci Signal. 2012;5(241):ra67.